Protalix Biotherapeutics (PLX) Set to Announce Quarterly Earnings on Wednesday

Protalix Biotherapeutics (NYSEAMERICAN:PLX) is set to issue its quarterly earnings data before the market opens on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $2.01 million during the quarter, compared to the consensus estimate of $7.00 million.

NYSEAMERICAN PLX opened at $0.50 on Tuesday. Protalix Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $0.83.

Several research analysts have commented on the company. Zacks Investment Research raised Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Tuesday, July 31st. HC Wainwright set a $4.00 target price on Protalix Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday, July 25th.

WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Featured Story: Bull Market

Earnings History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply